LGND vs PRGO vs INVA vs OMAB vs RPRX

For growth investors, Ligand Pharmaceuticals Incorporated (LGND) is the stronger pick with 27.

3% revenue growth year-over-year, versus -2. 8% for Perrigo Company plc (PRGO). Innoviva, Inc. (INVA) offers the better valuation at 6. 9x trailing P/E (11. 9x forward), making it the more compelling value choice. Analysts rate Ligand Pharmaceuticals Incorporated (LGND) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Innoviva, Inc.

(INVA) is the cheapest at 6. 9x versus Royalty Pharma plc at 27. 9x. On forward P/E, Grupo Aeroportuario del Centro Norte, S. A. B. de C. V. is actually cheaper at 0. 8x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Grupo Aeroportuario del Centro Norte, S. A. B. de C. V. wins at 0. 02x versus Royalty Pharma plc's 1. 45x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Grupo Aeroportuario del Centro Norte, S.

A. B. de C. V. (OMAB) delivered a total return of +157. 8%, compared to -60. 1% for Perrigo Company plc (PRGO). Over 10 years, the gap is even starker: OMAB returned +192. 8% versus PRGO's -77. 7%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Innoviva, Inc.

(INVA) is the lower-risk stock at 0. 13β versus Perrigo Company plc's 1. 18β — meaning PRGO is approximately 837% more volatile than INVA relative to the S&P 500. On balance sheet safety, Ligand Pharmaceuticals Incorporated (LGND) carries a lower debt/equity ratio of 1% versus 135% for Perrigo Company plc — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Ligand Pharmaceuticals Incorporated (LGND) is pulling ahead at 27.

3% versus -2. 8% for Perrigo Company plc (PRGO). On earnings-per-share growth, the picture is similar: Innoviva, Inc. grew EPS 816. 7% year-over-year, compared to -723. 2% for Perrigo Company plc. Over a 3-year CAGR, OMAB leads at 10. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Innoviva, Inc.

(INVA) is the more profitable company, earning 63. 8% net margin versus -33. 5% for Perrigo Company plc — meaning it keeps 63. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RPRX leads at 65. 6% versus -13. 5% for LGND. At the gross margin level — before operating expenses — RPRX leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Grupo Aeroportuario del Centro Norte, S. A. B. de C. V. (OMAB) is the more undervalued stock at a PEG of 0. 02x versus Royalty Pharma plc's 1. 45x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Grupo Aeroportuario del Centro Norte, S. A. B. de C. V. (OMAB) trades at 0. 8x forward P/E versus 23. 6x for Ligand Pharmaceuticals Incorporated — 22. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PRGO: 70. 6% to $20. 00.

In this comparison, PRGO (9.

8% yield), OMAB (5. 0% yield), RPRX (1. 3% yield) pay a dividend. LGND, INVA do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Royalty Pharma plc (RPRX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

45), 1. 3% yield). Both have compounded well over 10 years (RPRX: +22. 9%, LGND: +73. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (LGND (Healthcare) and PRGO (Healthcare) and INVA (Healthcare) and OMAB (Industrials) and RPRX (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: LGND is a small-cap high-growth stock; PRGO is a small-cap income-oriented stock; INVA is a small-cap high-growth stock; OMAB is a small-cap deep-value stock; RPRX is a mid-cap quality compounder stock. PRGO, OMAB, RPRX pay a dividend while LGND, INVA do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.